Efficacy of venlafaxine in depressed patients after switching from prior SSRI treatment

Reynaert, C.; Janne, Pascal; Zdanowicz, Nicolas; Mignon, A.

doi:10.1016/s0924-977x(00)80188-1

Cited by 1 publication

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Venlafaxine is also used in TRD as a "next-step" strategy (de Montigny et al, 1999;Kaplan, 2002;Mbaya, 2002;Mitchell et al, 2000;Montes et al, 2004;Nierenberg et al, 1994b;Poirier and Boyer, 1999;Reynaert et al, 2000;Saiz-Ruiz et al, 2002;Schweitzer et al, 2001), and in one large survey of clinicians was reported to be the most popular switch strategy for refractory depression (Kornbluh et al, 2001). There is also anecdotal evidence for the use of venlafaxine as an adjunct in the treatment of resistant depression (Gomez Gomez and Teixido Perramon, 2000), although toxicity may occur when venlafaxine is added to SSRIs since it is a substrate sfor CYP-450-2D6 (Benazzi, 1997), and for the use of venlafaxine as monotherapy in patients with MDD and co-morbid ADHD (Hornig-Rohan and .…”

Section: Serotonin and Norepinephrine Reuptake Inhibitors (Snris)mentioning

confidence: 99%

Monoaminergic‐based Pharmacotherapy for Depression

Papakostas¹,

Fava²

2005

Biology of Depression

View full text Add to dashboard Cite

Although recent advances in neuropharmacology, neuroendocrinology, molecular biology, and pharmacogenetics have been instrumental in bringing about potential treatments for depression which are fundamentally unrelated to their predecessors, including substance P antagonists, glutaminergic agents, and corticotropinreleasing factor (CRF) antagonists, nevertheless it was agents that influenced the function of monoamine receptors and transporters that were discovered initially by serendipity and then developed as treatments for depression. The development of such compounds also served as a framework for the understanding of depression as a medical illness affecting brain functioning. As a result of these efforts, our field has gained further understanding of the role of monoamines in depression. In previous chapters, the relevance of monoamines in the underlying pathophysiology of depression was reviewed. In the following chapter we will focus on describing the contemporary role of monoaminergic agents in the treatment of depression. 6.

show abstract